An optimization layer for existing CAR-T therapies

NanoKar is not a competing CAR-T. Our ITAM tuning platform works inside the CD3ζ signaling domain that every approved CAR-T shares, addressing the persistence and toxicity barriers limiting the field today, with preclinical signs of efficacy in solid tumors.

Full data package and mutual NDA available on request.
info@nanokartherapeutics.com